|
Oct 4
|
Altamira Therapeutics Provides Update on Nasdaq Listing
|
|
Sep 27
|
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
|
|
Aug 26
|
REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
|
|
Aug 16
|
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
|
|
May 28
|
Altamira Therapeutics Provides Business Update
|
|
May 23
|
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
|
|
May 1
|
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
|
|
Apr 24
|
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
|
|
Apr 17
|
Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024
|
|
Apr 10
|
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
|
|
Apr 4
|
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
|
|
Mar 25
|
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
|
|
Dec 5
|
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
|
|
Nov 29
|
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
|
|
May 1
|
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
|